About the Program
NNZ-2591 is a synthetic analog of a peptide that is related to IGF-1, a growth factor that is stimulated by growth hormone. IGF-1 in the brain is thought to be critical for normal brain development and to maintain biological balance by reducing inflammation, restoring normal cell function of the cells that surround neurons of the brain, and improve the function at the junction of the neurons.
- FAST Pillar
- Pillar 4: Targeting Downstream Pathways
- Investigational Drug Name
- NNZ-2591
- Company Website
- Neuren Pharmaceuticals
▶Program News
COMPLETED: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome (AS-001)
/news/neuren-pharmaceuticals-announced-top-line-results-from-its-phase-2-clinical-trial-of-nnz-2591-in-children-with-angelman-syndrome-as/
Read More